Who are Naloxone, intranasal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SAMIDORPHAN L-MALATE, BENZHYDROCODONE, NALBUPHINE HYDROCHLORIDE, Methadone Hydrochloride, XR-NTX 380 mg, intramuscular injection, Oral Naltrexone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/naloxone-intranasal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Naloxone, intranasal — Competitive Intelligence Brief

Naloxone, intranasal (Naloxone, intranasal) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: opioid antagonist. Area: Emergency Medicine.

phase 3 opioid antagonist opioid receptors Emergency Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Naloxone, intranasal (Naloxone, intranasal) — Norwegian University of Science and Technology. Naloxone reverses opioid overdose by competitively binding to opioid receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naloxone, intranasal TARGET	Naloxone, intranasal	Norwegian University of Science and Technology	phase 3	opioid antagonist	opioid receptors
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
XR-NTX 380 mg, intramuscular injection	XR-NTX 380 mg, intramuscular injection	University of Pennsylvania	marketed	Opioid receptor antagonist	Mu opioid receptor (primary); delta and kappa opioid receptors
Oral Naltrexone	Oral Naltrexone	New York State Psychiatric Institute	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (opioid antagonist class)

Bausch Health Americas, Inc. · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class
Norwegian University of Science and Technology · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Naloxone, intranasal — Competitive Intelligence Brief. https://druglandscape.com/ci/naloxone-intranasal. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab